# US 2015/0105326 A1 · Methyl degron peptide and methods of controlling protein lifespan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105326 A1
- Document ID: US20150105326A1
- Status: Published application
- Kind: A1
- Application number: 14/051,547
- Filed: 2013-10-11
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Seoul National University (SNU) R&D Foundation
- Applicants: Seoul National University (SNU) R&D Foundation
- Inventors: Sung Hee BAEK
- Web page: https://patentgrep.com/patent/US20150105326A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 35/00: Antineoplastic agents
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/90: containing a motif for post-translational modification
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene.

## Claims

### Claim 1

An isolated methyl degron peptide.

### Claim 2 (depends on 1)

The isolated methyl degron peptide of claim 1, wherein the peptide is methylated by Enhancer of Zeste Homolog 2 lysine methyltransferse (EZH2).

### Claim 3 (depends on 1)

The isolated methyl degron peptide of claim 1, wherein the peptide is recognized by DDB1-CUL4-associated factor 1 adaptor (DCAF1).

### Claim 4 (depends on 1)

The isolated methyl degron peptide of claim 1, wherein the peptide is involved in ubiquitin-dependent protein degradation.

### Claim 5 (depends on 1)

The isolated methyl degron peptide of claim 1, wherein the peptide is SEQ ID NO: 1.

### Claim 6 (depends on 5)

A fusion protein comprising the methyl degron peptide of claim 5.

### Claim 7 (depends on 6)

The fusion protein of claim 6, wherein the protein has reduced lifespan.

### Claim 8 (depends on 7)

The fusion protein of claim 7, wherein the fusion protein has a carcinogenic effect.

### Claim 9 (depends on 1)

A protein having an extended lifespan obtained by mutation of the methyl degron peptide of claim 1.

### Claim 10 (depends on 9)

The protein of claim 9, wherein the protein has an anticancer effect due to its extended lifespan.

### Claim 11 (depends on 5)

A method of regulating protein lifespan, comprising utilizing the methyl degron peptide of claim 5.

### Claim 12

A method for screening an agent that controls protein lifespan, the method comprising:
(a) culturing a cell;
(b) treating the cell with a potential agent;
(c) analyzing the methylation level of a methyl degron peptide in the cell; and
(d) determining the potential agent to be an agent that reduces protein lifespan, when the methylation level is increased, and determining the potential agent to be an agent that increases protein lifespan, when the methylation level is decreased.

### Claim 13

A method for screening an anti-cancer agent, the method comprising:
(a) culturing a cell;
(b) treating the cell with a potential agent;
(c) analyzing the degree of methylation of a methyl degron peptide in the cell;
(d) determining the potential agent to reduce protein lifespan, when the methylation level is increased, and determining the potential agent to increase protein lifespan, when the methylation level is decreased; and
(e) determining the methylated protein to be a carcinogenesis-related protein and determining the lifespan of the carcinogenesis-related protein to be reduced.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer is any one selected from the group consisting of breast cancer, liver cancer, bladder cancer, cervical cancer, colorectal cancer, kidney cancer, lung cancer, prostate cancer, pancreatic cancer, stomach cancer, and uterine cancer.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cancer is any one selected from breast cancer and prostate cancer.

### Claim 16 (depends on 1)

A method of treating cancer, the method comprising administering to a subject in need thereof a composition comprising the methyl degron peptide of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the lifespan of an anticancer-related protein is extended by mutating the methyl degron peptide sequence.

### Claim 18 (depends on 16)

The method of claim 16, wherein the lifespan of a carcinogenesis-related protein is shortened by inserting the methyl degron peptide sequence.

### Claim 19

A recombinant vector comprising a methyl degron gene of SEQ ID NO: 2.

### Claim 20 (depends on 19)

A transformed host cell comprising the recombinant vector of claim 19.
